**Supplementary data**

|  |  |  |
| --- | --- | --- |
| **Nosocomial infections** | **Primary Prophylaxis****(n=22)** | **Secondary Prophylaxis****(n=30)** |
| Gram-positive | 8 (37%) |  7 (23%) |
| Gram-negative | 3 (14%) | 8 (26%) |
| Fungus | 0 (0)% | 1 (3%) |
| No organism found | 6 (27%) | 4 (13%) |
| *Type of Infection* |  |  |
| SBP | 1 (5%) | 9 (29%)\* |
| Spontaneous Bacteremia | 2 (10%) | 4 (13%) |
| Respiratory | 3 (14%) | 2 (6%) |
| Skin/Soft-Tissue | 1 (5%) | 1 (3%) |
| Urinary Tract | 6 (27%) | 7 (23%) |
| *C.difficile* | 0 (0%) | 0 (0%) |
| Others | 9 (41%) | 7 (23%) |
|  | **Positive Isolates(n=11)** | **Positive isolates****(n=16)** |
| VRE | 1 (9%) | 2 (13%) |
| MRSA | 2 (18%) |  0 (0%) |
| Fluoroquinolone resistance | 3 (28%) | 2 (13%) |

**Table S2: Details of patients who developed a nosocomial infection (n=52)**

 \* p<0.05 Fisher exact test, VRE: vancomycin-resistant Enterococcus, MRSA: methicillin resistant Staphylococcus aureus